Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune Inc (THAR) is a clinical-stage biotechnology company pioneering treatments for rare immune and inflammatory disorders through innovative buccal film delivery and multispecific antibody platforms. This page provides timely updates on their therapeutic pipeline, including the TH104 program for primary biliary cholangitis (PBC) and early-stage immuno-oncology candidates.
Investors and industry observers will find authoritative coverage of clinical trial milestones, regulatory interactions with agencies like the FDA, and strategic partnerships. Our news collection focuses on scientifically validated developments, including progress in Phase 1/2 studies and novel drug delivery advancements.
Key updates include trial design approvals, patient recruitment status, pharmacokinetic data disclosures, and licensing agreements impacting therapeutic development. All content is vetted for accuracy and relevance to long-term value creation in rare disease markets.
Bookmark this page for consolidated access to Tharimmune's verified progress reports and scientific presentations. Check regularly for neutral, comprehensive updates on their mission to address unmet needs in chronic pruritus management and cancer immunotherapy.
Tharimmune (NASDAQ: THAR) commented on the DTCC and Digital Asset partnership to tokenize U.S. Treasury securities on the Canton Network announced December 18, 2025. The company highlighted that DTCC custody covers ~$30 trillion in U.S. Treasuries and noted Canton Network's $9 trillion monthly transaction volume and >700,000 daily transactions as validation of institutional blockchain adoption.
Tharimmune said it established a digital asset treasury strategy in November 2025 with a $545 million private placement, has acquired Canton Coin, and is pursuing roles as a Super Validator and application investor to support Canton Network expansion.
Tharimmune (NASDAQ: THAR) appointed Jacob Asbury as Chief Financial Officer, effective December 12, 2025. Mr. Asbury will oversee capital planning, treasury management, financial reporting, and expansion of Tharimmune’s Canton Coin (CC) treasury infrastructure.
The company said Asbury brings nearly two decades of experience, including prior CFO roles at Clear Street Group, Performance Flight & Custom Jet Charters, and Instinet, and holds a B.S. from the University of Vermont. Tharimmune established its differentiated digital asset treasury (DAT) strategy in November 2025 and is applying to operate as a Super Validator while investing in Canton Network applications. Tharimmune is the first publicly traded company to leverage CC and is supported by the Canton Foundation.
Tharimmune (Nasdaq: THAR) received positive FDA feedback on its TH104 (nalmefene buccal film) pharmacokinetic simulation modeling plan following a Type D meeting on Nov 13, 2025. The FDA concurred with the proposed modeling approach and gave technical guidance to incorporate into the final plan, supporting the company's pathway toward a 505(b)(2) NDA. Tharimmune is also initiating a CMC plan to scale production and ensure product quality for advanced development.
PK simulations projected a ~30-minute onset to target concentration and ~24-hour sustained protective levels versus current naloxone effects of 30–90 minutes.
Tharimmune (NASDAQ: THAR) closed a private placement on Nov 6, 2025, raising approximately $545 million gross by selling common shares (or pre-funded warrants) at $3.075 per share. Net proceeds are intended to acquire Canton Coin (CC), fund operation as a Super Validator, run additional validators, and support application development on the Canton Network, with remaining proceeds for working capital and general corporate purposes.
Led by DRW and Liberty City Ventures, investors include ARK Invest, Polychain, Kraken, Broadridge, Tradeweb Markets, and the Canton Foundation, making Tharimmune the first public company supported by the Canton Foundation.
Tharimmune (NASDAQ: THAR) announced a private placement to raise approximately $540 million at $3.075 per share, led by DRW and Liberty City Ventures with participation from institutional investors including ARK Invest, Kraken, Polychain, and the Canton Foundation. The proceeds are intended to buy Canton Coin (CC), fund a diversified digital-asset-treasury (DAT) strategy, and support working capital. Tharimmune plans to operate as a Super Validator and run additional validators to generate CC rewards and to invest in Canton Network applications. Closing is expected on or about November 6, 2025, subject to customary conditions.
Management appointed Mark Wendland as CEO for the digital asset treasury strategy and Mark Toomey as President; the biotech business remains under existing management. Canton reported >500,000 daily transactions as of Sept 30, 2025.
Tharimmune (Nasdaq:THAR) announced positive pharmacokinetic simulation results for TH104, its buccal film formulation of nalmefene, designed as a prophylactic treatment against respiratory depression from fentanyl and ultrapotent opioids.
The simulation analysis revealed that TH104 achieves protective effects within 30 minutes post-dose and maintains protection for approximately 24 hours, potentially offering superior duration compared to existing treatments like naloxone. The non-injectable buccal delivery system provides rapid absorption and convenient administration for first responders and military personnel.
Notably, the FDA previously indicated that no additional clinical trials appear necessary before a 505(b)(2) New Drug Application submission, streamlining the path to potential approval.
Tharimmune (Nasdaq:THAR) has secured significant global patent protection for TH-104, its novel transmucosal film technology, extending coverage until at least 2040. The patents, granted in Japan, Mexico, Australia, and the United States, cover a unique method for administering nalmefene via a single-layer, mucoadhesive film.
The FDA has provided positive feedback on TH-104's NDA pathway, confirming that a 505(b)(2) submission is viable for preventing respiratory and CNS distress, with no additional clinical trials required for military and first responder use against weaponized opioids. The drug features a longer half-life compared to existing alternatives like Narcan®, potentially providing sustained protection in high-risk environments.
Tharimmune (NASDAQ:THAR) has appointed renowned philanthropist Nancy Davis to its Board of Directors. Davis, founder of Race to Erase MS and Cure Addiction Now (CAN), brings extensive experience in patient advocacy and medical research advancement. Her organization Race to Erase MS has raised over $56 million for MS research through its "Center Without Walls" program, contributing to the development of FDA-approved therapies like Ocrevus®, Briumvi®, and Kesimpta®.
Davis's appointment is particularly significant as Tharimmune advances TH104, their investigational product being developed as a countermeasure against weaponized fentanyl for military use and chemical incident responders, with potential applications in addressing the opioid crisis. Her experience with CAN, which focuses on innovative addiction treatment research, aligns with Tharimmune's mission to develop breakthrough therapies for inflammation, immunology, and critical unmet medical needs.
Tharimmune (NASDAQ:THAR) provided a comprehensive corporate update highlighting two key programs and recent financing. The company raised $5.47 million in equity financing during Q2/Q3 2025.
Their lead asset TH104, a buccal film formulation of nalmefene, is being developed as a critical national security solution against weaponized fentanyl. The FDA has confirmed no additional clinical trials are needed before NDA submission via the 505(b)(2) pathway. The drug offers advantages over existing solutions with a longer half-life of 8-11 hours.
The company's second program, TH023, is developing an oral formulation of infliximab (TNF-alpha inhibitor) for inflammatory conditions. Preclinical studies have demonstrated successful oral delivery achieving significant therapeutic levels. The company plans to initiate first-in-human trials within 12 months.
Tharimmune (NASDAQ:THAR), a clinical-stage biotech company, has announced the pricing of a $1.74 million registered direct public offering of common stock and warrants. The offering includes 414,331 shares of common stock and 559,910 pre-funded warrants, along with 974,241 warrants to acquire common stock at an exercise price of $1.66 per share.
The units, comprising one share of common stock or pre-funded warrant and a common warrant, are priced at $1.786 per unit. President Street Global, LLC serves as the exclusive placement agent. The offering is expected to close around July 25, 2025, with proceeds intended for working capital and general corporate purposes.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
